Momenta Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript

Momenta Pharmaceuticals, Inc. (MNTA)

Q2 2010 Earnings Call Transcript

August 2, 2010 10:00 am ET

Executives

Beverly Holley – Director, IR

Craig Wheeler – President and CEO

Rick Shea – SVP and CFO

Analysts

Bret Holley – Oppenheimer

Ritu Baral – Canaccord

Simos Simeonidis – Rodman & Renshaw

Eric Schmidt – Cowen and Company

Joseph Schwartz – Leerink Swann

Eric Wold – Monness, Crespi, Hardt

Owen Gibbs [ph] – Rabbass [ph]

Lynne Yati [ph] – Stockstock Partners [ph]

Presentation

Operator

Compare to:
Previous Statements by MNTA
» Momenta Pharmaceuticals Inc. Q1 2010 Earnings Call Transcript
» Momenta Pharmaceuticals, Inc. Q4 2009 Earnings Call Transcript
» Momenta Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript

Good day, ladies and gentlemen and welcome to the Momenta Pharmaceutical Second Quarter 2010 Earnings Call. At this time, all participants are in a listen-only mode. Later, we’ll conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this conference is being recorded. I’ll now introduce your host for today, Ms. Beverly Holley, Director of Investor Relations. Ma’am, please go ahead.

Beverly Holley

Thank you and good morning. I want to welcome all of you to Momenta's conference call to discuss financial results for the second quarter of 2010 and provide a corporate update. With me on the call today with prepared remark are Craig Wheeler, President and Chief Executive Officer and Rick Shea, Senior Vice President and Chief Financial Officer. Following our remarks, we'll open the call to questions.

Before we begin, I'd like to mention that our call today will contain forward-looking statements. Various remarks that Momenta Pharmaceuticals may make about management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to our beliefs regarding the potential commercial market for generic enoxaparin, the potential for other generic enoxaparin product received FDA approval. The FDA has reviewed generic Copaxone, our product development plans, the company's revenue, expenses and other results of operations, including the quarter ended June 30, 2010 and current and future development efforts and commercialization efforts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.